Fujifilm, parent company of Fujifilm Medical Systems USA, announced it has received approval to begin offering its new artificial intelligence (AI) chest x-ray software in Japan.
Japan's Pharmaceuticals and Medical Devices Agency granted approval of CXR-AID, a software application developed with core AI technology by Lunit, a partner of Fujifilm since 2018. CXR-AID is designed to better detect major abnormal findings such as chest nodules, consolidation, and pneumothorax from chest x-ray images.
CXR-AID will be distributed across hospitals and medical institutions in Japan via Synapse, Fujifilm's PACS software platform.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
